Drug Profile


Alternative Names: Human immunoglobulin G1 kappa monoclonal antibody; MEDI-4893

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Biosynexus; GlaxoSmithKline; Regeneron Pharmaceuticals
  • Developer MedImmune
  • Class Anti-infectives; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia
  • Phase I Staphylococcal infections

Most Recent Events

  • 08 Sep 2014 Phase-II clinical trials in Nosocomial pneumonia (Prevention) in Belgium (IV)
  • 31 May 2014 MedImmune completes a phase I trial in Healthy volunteers in USA (NCT01769417)
  • 17 Sep 2013 MedImmune completes enrolment in its phase I trial in Healthy volunteers in USA (NCT01769417)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top